Showing results (251-260 of 276) with videos related to

Sort By:
Pageof 28
Blood|October 25, 2017
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphomaThierry Lamy, Gandhi Damaj, Pierre Soubeyran, et al.
Blood|November 19, 2020
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSASteven Le Gouill, Hervé Ghesquières, Lucie Oberic, et al.
Science Translational Medicine|December 3, 2010
Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type IAshley D Dierenfeld, Michael F McEntee, Carole A Vogler, et al.
JAMA Oncology|March 1, 2019
Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMTAbraham S Kanate, Ambuj Kumar, Peter Dreger, et al.
The Lancet. Haematology|December 15, 2016
Consolidation anti-CD22 fractionated radioimmunotherapy with 90Y-epratuzumab tetraxetan following R-CHOP in elderly patients with diffuse large B-cell lymphoma: a prospective, single group, phase 2 trialFrançoise Kraeber-Bodere, Amandine Pallardy, Hervé Maisonneuve, et al.
Blood Advances|September 18, 2025
Poor Outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jerome Lambert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 25, 2019
Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA StudyEmmanuel Bachy, John F Seymour, Pierre Feugier, et al.
Scientific Reports|August 22, 2025
Interlaboratory validation of an optimized protocol for measuring α-amylase activity by the INFOGEST international research networkDaniela Freitas, Shannon Gwala, Gwénaële Henry, et al.
Blood Advances|August 20, 2024
Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapyVincent Camus, Roch Houot, Gabriel Brisou, et al.
Blood Advances|February 24, 2026
Poor outcomes with BCMA-targeting bispecific antibodies following early relapse from ide-cel: a real-world French studySarah Cayla, Lionel Karlin, Jérôme Lambert, et al.
Pageof 28